Last updated on November 2019

A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Brief description of study

This study is to evaluate the safety and efficacy of 2 dose levels of risankizumab in adult participants with moderate to severe Hidradenitis Suppurativa (HS). This study includes two treatment periods. In Period A, participants are randomized to receive either risankizumab dose A, dose B, or placebo. In Period B, participants who received risankizumab dose A or placebo during Period A, will receive risankizumab dose B. Participants who received risankizumab dose B in Period A will remain on that dose in Period B.

Clinical Study Identifier: NCT03926169

Find a site near you

Start Over

Bravis Ziekenhuis /ID# 212536

Bergen op Zoom, Netherlands
  Connect »

Hamzavi Dermatology /ID# 212318

Fort Gratiot, MI United States
  Connect »

Hopital Nord /ID# 212564

Saint Priest En Jarez, France
  Connect »